NRX Pharmaceuticals Inc

NRXP

2.660USD

-0.080-2.92%

Close 11/05, 16:00（ET）Quotes delayed by 15 min

NRX Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

261 / 501

Overall Ranking

468 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Buy

Current Rating

36.500

Target Price

+1232.12%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

NRX Pharmaceuticals Inc Highlights

StrengthsRisks

NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic. The Company is also engaged in the development of its new product, NRX-102.

Fairly Valued

The company’s latest PE is -1.42, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 6.05M shares, increasing 36.88% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 452.18K shares of this stock.

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change

0



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

The company’s current valuation score is 6.22, which is lower than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -1.42, which is -155.35% below the recent high of 0.78 and -1871.23% above the recent low of -27.94.

Score

Industry at a Glance

Previous score

6.22

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 261/501

No Data

The company’s current earnings forecast score is 8.50, which is higher than the Biotechnology & Medical Research industry's average of 8.04. The average price target for NRX Pharmaceuticals Inc is 37.00, with a high of 46.00 and a low of 25.00.

Score

Industry at a Glance

Previous score

8.50

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 6.13, which is lower than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 3.67 and the support level at 2.78, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.95

Change

0.18

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated: 2025-10-27

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 25.47%, representing a quarter-over-quarter decrease of 13.11%. The largest institutional shareholder is The Vanguard, holding a total of 452.18K shares, representing 1.90% of shares outstanding, with 15.50% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

B Group, Inc.

3.00M

--

Anson Funds Management LP.

1.60M

+36.12%

Javitt (Jonathan C)

1.52M

-0.01%

Glytech LLC

963.48K

--

The Vanguard Group, Inc.

Star Investors

452.18K

+16.26%

AdvisorShares Investments, LLC

263.80K

-8.02%

Hurvitz (Chaim)

221.48K

+0.00%

Geode Capital Management, L.L.C.

172.25K

+27.92%

UBS Financial Services, Inc.

121.61K

+115717.14%

Citadel Advisors LLC

92.36K

--



1

2



There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 1.77. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

NRX Pharmaceuticals Inc

NRXP

4.16 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

CytomX Therapeutics Inc

CTMX

8.54 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

NewAmsterdam Pharma Company NV

NAMS

8.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Insmed Inc

INSM

8.50 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Amicus Therapeutics Inc

FOLD

8.49 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment